A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg

• Not currently taking BP-lowering medication

• Clinician recommends pharmacologic treatment

• Willing to make necessary study visits

• Able to be contacted by phone

• Has a primary care clinician

• At least 18 years old

Locations
United States
North Carolina
UNC Chapel Hill
Chapel Hill
Time Frame
Start Date: October 2012
Completion Date: July 2014
Participants
Target number of participants: 17
Treatments
Experimental: PRA-guided therapy
Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
Active Comparator: Fixed-dose combination treatment-guided therapy
Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
Related Therapeutic Areas
Sponsors
Collaborators: Cornell University, Wake Forest University Health Sciences
Leads: University of North Carolina, Chapel Hill

This content was sourced from clinicaltrials.gov

Similar Clinical Trials